Loading clinical trials...
Loading clinical trials...
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Conditions
Interventions
SQZ-PBMC-HPV
Atezolizumab
+2 more
Locations
12
United States
HonorHealth
Scottsdale, Arizona, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
University of Colorado Anschutz Cancer Pavillion
Aurora, Colorado, United States
University of Kansas Cancer Center
Kansas City, Kansas, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
The Masonic Cancer Center University of Minnesota
Minneapolis, Minnesota, United States
Start Date
January 28, 2020
Primary Completion Date
February 9, 2023
Completion Date
February 9, 2023
Last Updated
April 14, 2023
NCT07098988
NCT06403436
NCT06059547
NCT02293954
NCT00483366
NCT00875004
Lead Sponsor
SQZ Biotechnologies
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions